DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET

Company Participants

Rick Pauls - President, Chief Executive Officer & Director
Scott Kellen - Chief Financial Officer & Company Secretary
Lorianne Masuoka - Chief Medical Officer

Conference Call Participants

Thomas Flaten - Lake Street
Chase Knickerbocker - Craig-Hallum
Matthew Caufield - H.C. Wainwright

Operator

Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

Before DiaMedica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note regarding forward-looking statements. In the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and the third quarter report on Form 10-Q. DiaMedica's SEC filings are available at www.sec.gov and on its website. Please also note that any comments made on today's call speak only as of today, November 14, 2024 and may no longer be accurate at the time of any replay or transcript rereading. DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, the phone lines will be open for questions.

I would now like to introduce your host for today's call, Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin.

Rick Pauls

Thank you, operator. Hello, everyone and welcome to our third quarter conference call. I'm joined this morning by Dr. Lorianne Masuoka, our Chief Medical Officer; and Scott Kellen, our Chief Financial Officer. We're making solid progress on both our stroke and preeclampsia programs and we expect 2025 to be a truly transformative year for our company and our shareholders.

Although activating our top U.S. sites in our AIS study has taken longer than anticipated, I'm pleased to report that we now have 13 of our top 15 sites, either fully activated or with signed clinical trial agreements, negotiating this agreement stage is typically the most time-consuming part of the site activation process. We anticipate that these sites, especially our top 5 will enroll a disproportionately large number of patients. Houston Methodist, the first of our top 5 sites to be activated went live in September.